An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

APTIOM®

Drug Information Related Patent
Hold Company
SUMITOMO PHARMA AM
Learn More
Dosage and Administration
TABLET;ORAL
Specification
200MG; 400MG; 600MG; 800MG
Indication
APTIOM® is indicated for the treatment of partial-onset epilepsy in patients 4 years of age and older.
Use
Instructions for Use
API
ESLICARBAZEPINE ACETATE
API Structure
We Supply
ESLICARBAZEPINE ACETATE
Note:

In-house Standard
Facility GMP
USMF/DMF in processing

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
106752872025/5/6
106953542025/5/6
107025362025/5/6
109127812028/10/23
113642472025/5/6
83724312030/4/17
92061352026/4/21
95662442028/10/23
96439292026/4/21
97507472032/8/24
97639542028/9/13
API Patent
Patent NoExpiration Date
92061352026/4/21
96439292026/4/21

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top